我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

可溶性ST2与慢性心力衰竭

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2018年第2期
页码:
236-239
栏目:
综述
出版日期:
2018-02-15

文章信息/Info

Title:
Soluble ST2 and chronic heart failure
作者:
颜 语 综述; 尹新华 审阅
（哈尔滨医科大学附属第一医院心内科，黑龙江 哈尔滨150001）
Author(s):
YAN Yu;  YIN Xin-hua
(Department of Cardiology, First Affiliated Hospital, Harbin Medical University, Harbin 150001, Heilongjiang, China)
关键词:
心力衰竭; ST2; 预后
Keywords:
heart failure;  ST2;  prognosis
分类号:
R446.1
DOI:
-
文献标识码:
A
摘要:
慢性心力衰竭（CHF）是各种心脏疾病的终末阶段，尽管诊疗手段日益进步，在中国CHF仍是严峻的健康问题。CHF预后较差，严重心衰患者1年死亡率高达50%。寻找特异、灵敏的生物标志物对CHF的诊断、治疗和预测不良预后有重要的临床意义。可溶性ST2由于不受年龄、体质量等影响而成为了研究的热点，多项研究表明sST2对CHF的诊断、预后及危险分层中都具有重要的临床意义。
Abstract:
Chronic heart failure is the end stage of various heart diseases. Despite improvements in diagnosis and therapy, chronic heart failure is a major medical problem in China. The prognosis of chronic heart failure is poor, and the mortality of severe heart failure is as high as 50%. It is of great clinical significance to find specific and sensitive biomarkers for the diagnosis, treatment and prognosis of chronic heart failure. Soluble ST2 has become a hotspot because it is not influenced by factors such as age and weight. Many studies have shown that sST2 is of great clinical significance for diagnosis, prognosis and risk stratification in chronic heart failure.

参考文献/References

[1]Tominaga S.A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor[J].FEBS Lett,1989,258(2):301-304.

[2]Schmitz J,Owyang A,Oldham E,et al.IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines[J].Immunity,2005,23(5):479-490.

[3]Weinberg EO,Shimpo M,De Keulenaer GW,et al.Expression and regulation of ST2,an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction[J].Circulation,2002,106(23):2961-2966.

[4]Mildner M,Storka A,Lichtenauer M,et al.Primary sources and immunological prerequisites for sST2 secretion in humans[J].Cardiovasc Res,2010,87(4):769-777.

[5]Sanada S,Hakuno D,Higgins LJ,et al.IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system[J].J Clin Invest,2007,117(6):1538-1549.

[6]Weinberg EO,Shimpo M,Hurwitz S,et al.Identification of serum soluble ST2 receptor as a novel heart failure biomarker[J].Circulation,2003,107(5):721-726.

[7]Ky B,French B,Mccloskey K,et al.High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure[J].Circ Heart Fail,2011,4(2):180-187.

[8]Daniels LB,Clopton P,Iqbal N,et al.Association of ST2 levels with cardiac structure and function and mortality in outpatients[J].Am Heart J,2010,160(4):721-728.

[9]Gruson D,Lepoutre T,Ahn SA,et al.Increased soluble ST2 is a stronger predictor of long-term cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fraction[J].Int J Cardiol,2014,172(1):e250-e252.

[10]Broch K,Ueland T,Nymo SH,et al.Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology[J].Eur J Heart Fail,2012,14(3):268-277.

[11]Gagging HK,Szymonifka J,Bhardwaj A,et al.Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitivity troponin T measurements in patients with chronic heart failure[J].JACC Heart Fail,2014,2(1):65-72.

[12]Anand IS,Rector TS,Kuskowski M,et al.Prognostic value of soluble ST2 in the Valsartan Heart Failure trial[J].Circ Heart Fail,2014,7(3):418-426.

[13]Persson H,Erntell H,Eriksson B,et al.Improved pharmacological therapy of chronic heart failure in primary care:a randomized study of NT-proBNP guided management of heart failure-SIGNAL-HF(Swedish Intervention study-Guidelines and NT-proBNP AnaLysis in Heart Failure)[J].Eur J Heart Fail,2010,12(12):1300-1308.

[14]Parikh RH,Seliger SL,Christenson R,et al.Soluble ST2 for Prediction of Heart Failure and Cardiovascular Death in an Elderly,Community-Dwelling Population[J].J Am Heart Assoc,2016,5(8).pii:e003188.doi:10.1161/JAHA.115.003188.

[15]Gagging HK,Motiwala S,Bhardwaj A,et al.Soluble concentrations of the interleukin receptor family member ST2 and beta-blocker therapy in chronic heart failure[J].Circ Heart Fail,2013,6(6):1206-1213.

[16]Weir RA,Miller AM,Murphy GE,et al.Serum soluble ST2:a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction[J].J Am Coll Cardiol,2010,55(3):243-250.

[17]Bayes-Genis A,Zamora E,De Antonio M,et al.Soluble ST2 serum concentration and renal function in heart failure[J].J Card Fail,2013,19(11):768-775.

[18]Bertoni AG,Hundley WG,Massing MW,et al.Heart failure prevalence, incidence, and mortality in the elderly with diabetes[J].Diabetes Care,2004,27(3):699-703.

[19]Alonso N,Lupón J,Barallat J,et al.Impact of diabetes on the predictive value of heart failure biomarkers[J].Cardiovasc Diabetol,2016,15(1):151.

[20]Bayes-Genis A,De Antonio M,Galan A,et al.Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure[J].Eur J Heart Fail,2012,14(1):32-38.

[21]Yancy CW,Jessup M,Bozkurt B,et al.2013 ACCF/AHA Guideline for the Management of Heart Failure:A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J].J Am Coll Cardiol,2013,128(16):1810-1852.

[22]Bayes-Genis A,De Antonio M,Villa J,et al.Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectine-3[J].J Am Coll Cardiol,2014,63(2):158-166.

备注/Memo

备注/Memo:
收稿日期：2017-02-20.通讯作者：尹新华，主任医师，主要从事高血压和心衰机制研究 Email:xinhua_yin@163.com 作者简介：颜语，硕士生 Email：yanyu0209@163.com
更新日期/Last Update: 1900-01-01